---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000069"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:02:02.078869+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arvinas reports preclinical combo data for PROTAC BCL6 degrader ARV-393 with complete regressions in lymphoma

## Summary
- ARV-393 plus R-CHOP induced complete tumor regressions in all mice, outperforming single agents alone.
- Combination with SOC biologics (rituximab, tafasitamab, polatuzumab vedotin) resulted in tumor regressions in DLBCL models.
- ARV-393 increased CD20 expression in preclinical models, supporting combinations with CD20-targeted agents.
- Combination with investigational SMIs (acalabrutinib, venetoclax, tazemetostat) showed superior growth inhibition with regressions.
- Phase 1 study for ARV-393 (NCT06393738) enrolling patients with relapsed/refractory non-Hodgkin lymphoma.

## SEC filing metadata
- accession: 0001655759-25-000069
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000069/0001655759-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000069/arvn-20250428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000069
- JSON: https://secwatch.observer/filing/0001655759-25-000069.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.